Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What to do with HLA-DO?

M van Ham1, M van Lith, A Griekspoor

  • 1Division of Tumor Biology, The Netherlands Cancer Institute, Amsterdam. vanham@nki.nl

Immunogenetics
|September 2, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].

Gynecologic oncology·2021
Same author

Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).

Gynecologic oncology·2021
Same author

Playing hide and seek: Tumor cells in control of MHC class I antigen presentation.

Molecular immunology·2021
Same author

Clinical auditing as an instrument to improve care for patients with ovarian cancer: The Dutch Gynecological Oncology Audit (DGOA).

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2021
Same author

No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.

Gynecologic oncology·2020
Same author

[Treatment evaluation and clinical decision making using HKT-30-ROM].

Tijdschrift voor psychiatrie·2014
Same journal

Genotype-phenotype correlations in autoimmune and autoinflammatory diseases: An NGS-based immunogenetic cohort study.

Immunogenetics·2026
Same journal

Elevated interleukin-36γ and gene polymorphisms implicate novel risk in essential hypertension.

Immunogenetics·2026
Same journal

Unraveling the genomic structures, conserved functional domains and evolutionary dynamics of beta-defensins in Bubalus bubalis and Ovis aries.

Immunogenetics·2026
Same journal

Genetic characterization of the TAPBP and its allelic association with BF2 in the chicken major histocompatibility complex.

Immunogenetics·2026
Same journal

Reconstructed amphibian heavy-chain constant regions support a mosaic origin of IgXA with IgY-like CH1-CH2, an intermediate CH3, and an IgM-like CH4.

Immunogenetics·2026
Same journal

Climate factors and selection shape MHC class II diversity in a montane wild sheep (Ovis ammon).

Immunogenetics·2026
See all related articles

Human Leukocyte Antigen-DM (HLA-DM) is a chaperone protein crucial for antigen presentation by MHC class II molecules. The newly discovered HLA-DO molecule interacts with HLA-DM, influencing its function, particularly in B cells.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Antigenic peptide binding to MHC class II molecules is a complex process.
  • HLA-DM acts as a specialized lysosomal chaperone, essential for this process.
  • HLA-DM shares structural homology with MHC class I and II molecules and is expressed in antigen-presenting cells.

Purpose of the Study:

  • To review the effects of the HLA-DO molecule on HLA-DM-mediated antigen presentation.
  • To discuss the physiological relevance of HLA-DO's B cell-specific expression and function.

Main Methods:

  • Review of existing literature on HLA-DM and HLA-DO function.
  • Analysis of structural and genetic homologies between HLA-DM, HLA-DO, and MHC molecules.
  • Evaluation of the impact of HLA-DO on HLA-DM activity in antigen presentation.

Related Experiment Videos

Main Results:

  • HLA-DM catalyzes the dissociation of unstable peptides from MHC class II, promoting stable antigenic peptide presentation.
  • HLA-DO associates with HLA-DM, significantly altering its function.
  • HLA-DO is primarily expressed in B cells, suggesting a specialized role in B cell immunity.

Conclusions:

  • HLA-DO plays a unique role in modulating HLA-DM activity during antigen presentation by MHC class II molecules.
  • The B cell-specific expression of HLA-DO indicates a critical function in B cell-mediated immune responses.
  • Further research is needed to fully elucidate the physiological implications of HLA-DO's interaction with HLA-DM.